This Week in Infectious Disease — Jul 3, 2026

Welcome to This Week in Infectious Disease. This week we are covering ten notable papers spanning three broad themes: optimizing antibiotic selection, dosing, and duration in bacteremia and focal infections; improving screening and diagnostic strategies for chronic and fastidious pathogens; and standardizing our clinical communication and research definitions to improve patient care. Let us dive in.

We begin with a critical question in bacteremia management: how long do we need to treat uncomplicated enterococcal bloodstream infections? Historically, enterococcal bacteremia has carried high mortality rates, often approaching 25 to 30 percent, yet robust evidence guiding optimal treatment duration has been limited. To address this, a multicenter target trial emulation published in Clinical Infectious Diseases evaluated short-course versus long-course therapy in adults hospitalized with uncomplicated monomicrobial enterococcal bloodstream infections [1]. Using a retrospective cohort across eight hospitals in Israel over a ten-year period, the investigators compared a short strategy of 7 plus or minus 2 days against a long strategy of 14 plus or minus 2 days. Out of 3,450 patients screened, 485 received treatment durations consistent with the study protocols. The results demonstrated no difference in 30-day all-cause mortality, which was 21.6 percent in the short-course group and 21.3 percent in the long-course group. Furthermore, there was no evidence of differences across secondary outcomes, including 90-day all-cause mortality, recurrence, length of stay, readmission, and Clostridioides difficile infection. This suggests that for appropriately selected patients with uncomplicated monomicrobial enterococcal bacteremia, a 7-day course of antibiotics is safe and effective, supporting shorter treatment durations in clinical practice. Staying with bloodstream infections, we turn to Staphylococcus aureus. Writing in the Journal of Antimicrobial Chemotherapy, researchers reviewed recent clinical trial results from the Staphylococcus aureus network adaptive platform, or SNAP trial, specifically focusing on methicillin-susceptible and penicillin-susceptible domains, alongside the CloCeBa trial [2]. For decades, guidelines have recommended intravenous flucloxacillin or cloxacillin as first-line therapy for methicillin-susceptible S. aureus bacteremia. However, the SNAP trial, which is the largest randomized clinical trial ever conducted in S. aureus bacteremia, revealed unexpectedly high rates of acute kidney injury when high doses of flucloxacillin or cloxacillin are used. The authors emphasize that the nephrotoxicity of these agents has been historically underrecognized, and they advocate for cefazolin as a safer, equally efficacious first-line alternative. Yet, switching to cefazolin is not without its own challenges, particularly regarding drug exposure. In another study published in the Journal of Antimicrobial Chemotherapy, investigators evaluated the incidence of subtherapeutic cefazolin levels in 70 patients with severe infections, 86 percent of whom had methicillin-susceptible S. aureus infections [4]. Using therapeutic drug monitoring, they defined subtherapeutic levels as a total trough drug concentration of less than 40 milligrams per liter. Alarmingly, subtherapeutic levels were observed in 39 percent of patients. Patients who received cefazolin via continuous infusion had significantly higher median drug levels compared to those receiving intermittent infusions, despite receiving similar total daily doses. Additionally, hypoalbuminemia, defined as an albumin level below 3 grams per deciliter, was strongly associated with having definitive endocarditis and lower cefazolin concentrations. This highlights a clinical paradox: while cefazolin is safer for the kidneys than flucloxacillin, clinicians must be vigilant about subtherapeutic dosing, particularly in patients with endocarditis and hypoalbuminemia, where continuous infusions or therapeutic drug monitoring may be necessary to ensure adequate drug exposure. When treating Gram-positive infections in deep tissue compartments, serum drug levels may not accurately reflect concentrations at the actual site of infection. A prospective, single-center study in the International Journal of Antimicrobial Agents explored this issue by evaluating vancomycin penetration into the ascites and bile of 39 critically ill patients with complicated intra-abdominal infections [7]. The researchers compared a serum-only therapeutic drug monitoring group with a dual-monitoring group that measured drug levels in both the serum and the local infection site fluid. The findings revealed a stark disparity in drug penetration: vancomycin penetrated well into ascitic fluid, reaching an average penetration rate of roughly 66 percent, but its penetration into bile was extremely poor, averaging only 18.5 percent. Remarkably, the dual-monitoring approach, which allowed for site-specific dose optimization, was associated with significantly higher clinical efficacy, rising from 57 percent in the serum-only group to 88 percent in the dual-monitoring group, and higher microbiological eradication. While this was a small, non-randomized study, it underscores that for biliary infections, standard vancomycin dosing is highly unlikely to achieve therapeutic levels, and clinicians should consider alternative anti-Gram-positive agents with better biliary clearance or utilize site-specific drug monitoring where feasible.

Our second theme focuses on optimizing how we detect infections and manage the care cascade for chronic and fastidious pathogens. We begin with a practical diagnostic update from Clinical Infectious Diseases regarding blood cultures for fastidious organisms [8]. While the volume of blood drawn is known to affect the sensitivity of cultures for common bacteria, its impact on fastidious fungi and mycobacteria has been less clear. In a brief report, investigators demonstrated that simply increasing the volume of blood collected by drawing two Myco/F Lytic bottles, containing 5 milliliters of blood each, rather than a single bottle, increased the recovery of fastidious mycobacteria and fungi by 24.1 percent. This is a simple, low-cost intervention that clinical microbiology labs and bedside clinicians can implement immediately to improve the diagnostic yield in patients suspected of having disseminated fungal or mycobacterial infections. Moving from the laboratory to public health, a large real-world analysis published in Open Forum Infectious Diseases documented the hepatitis C virus care cascade and screening modalities among over 61,000 individuals tested in Ontario, Canada, between 2010 and 2023 [9]. The overall antibody prevalence was 13.6 percent, peaking at over 23 percent in individuals aged 35 to 44, and reaching 41 percent in addiction clinics. However, the study revealed significant attrition along the care cascade: only 79.7 percent of antibody-positive individuals underwent confirmatory RNA testing. Of those who were RNA-positive, 65 percent attended a follow-up appointment, and while 94 percent of those who made it to their appointment initiated treatment, only 28.2 percent of the total RNA-positive population had documented sustained virologic response 12 weeks after completing therapy. The authors found that primary care settings were the most effective at linking patients to care, and they concluded that matching the optimal antibody testing modality to the specific clinical or community setting, while building robust, direct pathways for confirmatory testing and follow-up, is essential to close these clinical gaps and meet global elimination targets. A similar challenge of clinical follow-up exists for tuberculosis survivors and their household contacts, who remain at high risk for developing active tuberculosis even after successful treatment completion. In the TB Aftermath trial, a multicenter, open-label, randomized non-inferiority trial conducted in India and published in The Lancet Global Health, researchers compared phone-based symptom screening against home-based screening at 6 and 12 months post-treatment [5]. The trial enrolled 1,076 tuberculosis survivors and 3,309 of their household contacts. Looking at the combined population of survivors and contacts, phone-based screening was found to be non-inferior to home-based screening for detecting active tuberculosis. However, when the investigators looked at tuberculosis survivors separately, they found a significant difference: the recurrence detection rate was nearly twice as high in the home-based screening group compared to the phone-based group, with rates of 8.00 versus 4.36 cases per 100 person-years. This indicates that while phone-based screening is a resource-efficient option for household contacts, active home-based visits remain superior for detecting disease recurrence in tuberculosis survivors living in high-burden countries.

Our final theme addresses the language we use in clinical practice and the definitions that guide our research. We start with a highly practical study from Clinical Infectious Diseases that examines how the language in our consultation notes affects patient care [3]. Infectious disease consultations are well known to improve patient outcomes, but the clarity of our recommendations matters. Researchers conducted a retrospective analysis of 1,087 recommendations made across 250 consecutive consults in a large hospital network. They found that nearly 10 percent of recommendations used ambiguous language, most commonly the word 'consider'. Adherence to clear, non-ambiguous recommendations was high, at over 87 percent. In contrast, when ambiguous language was used, adherence dropped to under 60 percent. In a multivariable analysis, recommendations containing ambiguous language were significantly less likely to be followed, representing roughly an 84 percent reduction in the odds of implementation. Ambiguous language was most frequently used for recommendations that were not immediately actionable. This study is a powerful reminder that if we want our recommendations to be followed, we must avoid hedging with words like 'consider' and instead provide clear, decisive, and actionable guidance. Just as clear communication is vital at the bedside, standardized definitions are essential for advancing clinical research. In the field of orthopedic infections, a meta-epidemiological study published in Open Forum Infectious Diseases reviewed 461 studies to assess how treatment success and failure are defined in prosthetic joint infections [6]. The authors found substantial heterogeneity, with clinical criteria being the most common, while patient-reported outcomes, histopathology, and antibiotic-related outcomes were rarely or inconsistently reported. To address this, they proposed a standardized core outcome set to harmonize future clinical trials and registries. Similarly, in the field of tropical medicine, a Delphi study published in The Lancet Infectious Diseases sought to establish expert consensus on case definitions for human loiasis, a filarial infection caused by Loa loa [10]. A panel of 18 experts achieved high consensus on the definitions of eyeworm, Calabar swelling, and the classification of possible, probable, and confirmed loiasis. Notably, the panel agreed to completely abandon the term 'occult loiasis' due to its inherent ambiguity. These standardized definitions will support the development of international diagnostic and management guidelines and ensure that future research is built on a shared, unambiguous scientific language.

If you only have time for one paper this week, make it the target trial emulation on enterococcal bloodstream infection duration published in Clinical Infectious Diseases [1]. This study provides much-needed, high-quality observational evidence that a seven-day course of antibiotics is safe and effective for uncomplicated enterococcal bacteremia, challenging the historical dogma of longer treatment durations and offering us a clear path to reduce unnecessary antibiotic exposure in our daily practice.

Here are the key takeaways from this week in Infectious Disease. First, for patients with uncomplicated monomicrobial enterococcal bloodstream infections, a short antibiotic course of seven days offers comparable clinical outcomes to a fourteen-day course, with no increase in mortality or recurrence. Second, when treating methicillin-susceptible S. aureus bacteremia, cefazolin is a safer alternative to high-dose flucloxacillin regarding renal function, but clinicians must watch for subtherapeutic levels, particularly in patients with endocarditis and hypoalbuminemia where continuous infusions should be considered. Third, vancomycin has very poor penetration into bile, meaning standard dosing is unlikely to achieve therapeutic levels in biliary infections, whereas its penetration into ascitic fluid is adequate. Fourth, in high-burden countries, home-based screening is superior to phone-based screening for detecting tuberculosis recurrence in survivors, though phone-based screening remains non-inferior for household contacts. Fifth, clarity in consultation matters; avoiding ambiguous words like 'consider' in your infectious disease recommendations can significantly improve primary team adherence to your clinical advice.

That's your roundup for This Week in Infectious Disease. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.